Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Together will work to develop cancer vaccines
March 14, 2017
By: Tim Wright
Editor-in-Chief, Contract Pharma
Vedantra Pharmaceuticals, an immunotherapy company focused on developing products for cancer and infectious disease, has formed a joint collaboration to explore cancer vaccine research with Neon Therapeutics, an immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer. The two companies will contribute their respective expertise non-exclusively to explore the potential benefits of combining Vedantra’s cutting edge albumin-binding, lymph node targeting amphiphile technology with Neon’s innovative capabilities in neoantigen vaccine research. “We are excited to work with Neon Therapeutics, a leading neoantigen company, on this joint research collaboration to explore the various vaccine opportunities that exist with both of our company’s programs. Although our albumin-binding amphiphile technologies have the potential to be effective at combating cancer by enhancing the body’s natural immune responses, our partnership has clear benefits to exploring innovative ways to synergistically enhance both of our programs,” said Julian Adams, executive chairman, Vedantra. “In addition to the continued development of Vedantra’s therapeutic technologies, we are pleased to move forward on a collaboration that could place both Vedantra and Neon at the forefront of cancer vaccine development.” “Vedantra’s focus on generating novel therapeutics leverages proprietary platform technologies that are able to deliver agents directly to antigen-presenting cells of the lymph nodes, and builds upon years of research that could be further enhanced through a collaboration with a company like Neon,” said Darrell Irvine, professor, departments of biological engineering and materials science and engineering, Massachusetts Institute of Technology, founder and scientific consultant, Vedantra. “We are excited for the opportunity to explore and evaluate the potential benefits of applying this technology to neoantigen-based vaccines.” Neoantigens, which are often associated with tumors, arise as a result of accumulating somatic mutations and foreign sources such as viruses. These alterations in a patient’s tumor DNA occur during the development and progression of tumors. The objective of the joint research collaboration is to continue development of therapeutic vaccines that raise immune responses against neoantigens that allow the body to naturally expand immune cells capable of destroying infected or cancerous cells without harming normal tissues.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !